NEW YORK – Celsius Therapeutics said Wednesday that it has signed collaboration agreements with the University of Oxford in the UK, the Cleveland Clinic in the US, and LMU University Hospital Munich in Germany to apply single-cell analytics technology to research into inflammatory bowel disease.
The Cambridge, Massachusetts-based vendor will lend its proprietary single-cell genomics platform and machine-learning technology to analyze longitudinal biopsies at three different stages.